

CURRICULUM VITAE

GENERAL INFORMATION

Name: Thomas Dörner, Prof. Dr. med.
Date of birth: [REDACTED]
Nationality: [REDACTED]

MAIN DOMAIN of RESEARCH

Clinical immunology/Rheumatology with a focus of the pathogenic role of B lineage cells as target of innovative treatments. Signaling pathways impacting on B cell functions. Heterogeneity of human plasma cell subsets. Early clinical trials of "proof of concept", "first in human", "first in patient".

SCIENTIFIC CAREER

since 2009 Professor „Innovative Therapies in Autoimmune Diseases“ at Charite and DRFZ, Berlin
since 2004 Head of Clinical Hemostaseology at Charite, Berlin
2004-2009 Head of Hemostasis department at the Institute of Transfusion Medicine and Immune Hematology, Charite Berlin
2004 Professor of Rheumatology/Head Rheumatology at Ludwig Maximilian Univ. Munich
1998 - 2000 Senior Resident, Dept. Medicine/Rheumatology and Clinical Immunology, Charite

EDUCATION

1998 PD Dr med Habilitation, Rheumatology/Clin. Immunology, Humboldt University/Charite Berlin, Germany
1996 - 1998 Post-Doc, Dept. Medicine/UT Southwestern Medical Center at Dallas, TX. USA

AWARDS

2010 Randy-Fischer Price by NIAMS, NIH, USA
2003 Wolfgang Schultze Price of the Stiftung Deutsche Rheumaliga e.V., Germany
2000 Rudolf-Schoen Price of the German Society of Rheumatology, Germany
1998 Senior Scholar Award of the ACR, USA

THIRD PARTY FUNDING (selection from 2017-ongoing)

2017 – current TR130 Characterization of bone marrow plasma cell subsets
2017 – current DFG projects Do491/9-1 "B cell functions in SLE" and Do491/7-3 "B cells in tissue"
2020- current Sino German (DFG) project (Do491/11-1) with Dr. Chu/Prof. Rajewsky (MDC) and Prof. Changchun Xiao (Xiamen, China) "Novel regulators of plasma cell differentiation"

TOP related PUBLICATIONS

- 1) **Dörner T**, Furie R. (2019) Novel paradigms in systemic lupus erythematosus. *Lancet*. 393(10188):2344-2358.
- 2) **Dörner T**, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L, Hüser A, Gram H, Wagner FD, Oliver SJ. (2019) Treatment of primary Sjögren's syndrome with ivalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. *Ann Rheum Dis*. 78(5):641-647
- 3) Lisney, A. R. Szelinski, F., Reiter, K., Burmester, G. R., Rose, T., **Dörner, T.** (2017) High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. *Ann Rheum Dis* **76**, 1476-1480.
- 4) **Dörner T.**, Posch, M.G., Li, Y., Petricoul, O., Cabanski, M., Milojevic, J.M., Kamphausen, E., Valentin, M.A., Simonett, C., Mooney, L., Hüser, A., Gram, H., Wagner, F.D., Oliver, S.J. (2019) Treatment of primary Sjögren's syndrome with ivalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. *Ann Rheum Dis*. 78(5):641-647
- 5) Giesecke, C., Meyer, T., Durek, P., Maul, J., Preiß, J., Jacobs, J.F.M., Thiel, A., Radbruch, A., Ullrich, R., **Dörner, T.** (2018) Simultaneous Presence of Non- and Highly Mutated Keyhole Limpet Hemocyanin (KLH)-Specific Plasmablasts Early after Primary KLH Immunization Suggests Cross-Reactive Memory B Cell Activation. *J Immunol*. Jun 15;200(12):3981-3992.